Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research
11:05am, Wednesday, 22'nd Jan 2025
The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12.89 billion in 2025 to USD 25.38 billion by 2033, growing at a CAGR of 8.84
AbbVie Cuts Its Guidance on ImmunoGen Deal
12:20pm, Monday, 12'th Feb 2024
Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.
AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
07:51am, Monday, 12'th Feb 2024
AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The co
AbbVie Completes Acquisition of ImmunoGen
07:37am, Monday, 12'th Feb 2024
Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGe
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
10:40am, Friday, 09'th Feb 2024
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
07:01am, Friday, 09'th Feb 2024
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
02:38pm, Tuesday, 06'th Feb 2024
As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a k
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 01'st Feb 2024
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
09:01am, Tuesday, 09'th Jan 2024
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
Cramer names biopharma companies to watch as industry mergers start to pile up
07:02pm, Friday, 05'th Jan 2024
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
01:32pm, Thursday, 04'th Jan 2024
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for January 4th
11:17am, Thursday, 04'th Jan 2024
IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.
New Strong Buy Stocks for January 4th
08:17am, Thursday, 04'th Jan 2024
IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 03'rd Jan 2024
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
08:30am, Tuesday, 26'th Dec 2023
AbbVie needs to diversify its drug portfolio because of the loss of exclusive rights to Humira. The recent acquisition of ImmunoGen fills several needs and comes at an excellent time.
